Evidence map›Paper›PMID 28577292›Full record

ArticleDrugs in R&D2017

A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.

Koichiro Homma, Joe Yoshizawa, Yutaka Shiina, Hideki Ozawa, Muneki Igarashi, Tadashi Matsuoka, Junichi Sasaki, Mamoru Yoshizawa, Yasuhiko Homma

Open access · goldAbstract readControlled Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs in R&D, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Renoprotective Effects of DPP-4 Inhibitors.Antioxidants (Basel, Switzerland) · 2021
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Koichiro HommaDepartment of Emergency and Critical Care Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8584, Japan. homma@keio.jp.
Joe YoshizawaDepartment of Emergency and Critical Care Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8584, Japan.
Yutaka ShiinaDepartment of Clinical Health Science, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Hideki OzawaDepartment of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Muneki IgarashiDepartment of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Isehara, 259-1193, Japan.
Tadashi MatsuokaDepartment of Emergency and Critical Care Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8584, Japan.
Junichi SasakiDepartment of Emergency and Critical Care Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8584, Japan.
Mamoru YoshizawaHiratsuka Lifestyle-Related Diseases and Hemodialysis Clinic, 11-14 Takaracho, Hiratsuka, 254-0034, Japan.
Yasuhiko HommaHiratsuka Lifestyle-Related Diseases and Hemodialysis Clinic, 11-14 Takaracho, Hiratsuka, 254-0034, Japan.
Keio University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveA high plasma level of remnant-like particle cholesterol (RLP-C), which is equivalent to triglyceride-rich lipoprotein remnant, is an important coronary risk marker. RLP-C level is high, independent of other plasma lipids, in patients with chronic kidney disease (CKD) undergoing hemodialysis. The effect of teneligliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, on plasma levels of RLP-C in patients with diabetes mellitus and CKD under hemodialysis was studied.

methodsTeneligliptin 20 mg/day was administered to 15 patients with diabetes and CKD undergoing hemodialysis for 12 weeks. Ten patients with diabetes and CKD undergoing hemodialysis were allocated to the control group. Blood was sampled following a 12-h fast. Fasting plasma glucose (FPG), C-peptide, triglyceride, low-density lipoprotein (LDL)-cholesterol (C), high-density lipoprotein (HDL)-C, RLP-C, apolipoprotein (apo) B, oxidized LDL, lipoprotein lipase, and glycated hemoglobin (HbA1c) were measured.

resultsHbA1c decreased in the teneligliptin group but significantly increased in the control group. FPG and RLP-C significantly decreased in the teneligliptin group. Plasma lipoprotein-related parameters except RLP-C were not affected by teneligliptin treatment.

conclusionTeneligliptin treatment significantly reduced plasma levels of RLP-C, FPG, and HbA1c in patients with diabetes with CKD who are undergoing hemodialysis.

Indexed as

Renal DialysisAgedBlood GlucoseCholesterolDiabetes MellitusDipeptidyl-Peptidase IV InhibitorsFemaleGlycated HemoglobinHumansHypoglycemic AgentsLipidsLipoproteinsMaleMiddle AgedPyrazolesRenal Insufficiency, Chronic3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidineBlood GlucoseCholesterolDipeptidyl-Peptidase IV InhibitorsGlycated HemoglobinHypoglycemic AgentsLipidsLipoproteinsPyrazolesremnant-like particle cholesterolThiazolidinesTriglycerides

Identifiers

PMID28577292
PMCPMC5629130
OpenAlexW2620877328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.